Novartis Secures Two FDA Approvals for Parkinson’s Drug Stalevo. Approbation.
Friday, November 7th, 2008Stalevo is approved to replacement immediate-release carbidopa/levodopa and entacapone in days administered as own Products, or to renew immediate-release carbidopa/levodopa therapy, without entacapone, in in the cards Parkinson’s contagion patients who are experiencing the signs and symptoms of end-of-dose "wearing off". Stalevo, originated and manufactured by Orion Corporation, was approved by the U.S. Food and Drug Administration (FDA) in June 2003 and is marketed in the United States by Novartis Pharmaceuticals Corporation.
Important Safety Information The most banal angle goods of Stalevo are unwanted or uncontrollable movements (known as dyskinesia), nausea, diarrhea, unconscionable Muscle movements (known as hyperkinesia), non-venomous discoloration of urine, sudor and/or saliva, diminished or hesitant movements (known as hypokinesia), abdominal Pain, dizziness, constipation, fatigue, Pain, and hallucinations. Some of the more severe insignificant gear may cover unyielding diarrhea, sparse dyskinesia, hallucinations, Other bananas disturbances, orthostatic hypotension (low Blood Pressure), rhabdomyolysis (a Muscle disease), and symptoms resembling neuroleptic invidious syndrome (a ready characterized by fever and Muscle stiffness). Be meticulous using Stalevo if you have cold fundamentals or lung disease, Asthma, renal, hepatic, or endocrine disease, or a experience of magnanimity attacks or ulcers. Do not lead Stalevo if you have glaucoma, melanoma, or Other kin medical disorders.
